These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 15760575

  • 1. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.
    Anderson P, Louie J, Lau A, Broder M.
    Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA, Agudo M.
    Med Clin (Barc); 2010 May 22; 134(15):684-5. PubMed ID: 20176386
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
    Neovius M, Askling J.
    Ann Rheum Dis; 2014 Jun 22; 73(6):e32. PubMed ID: 24638970
    [No Abstract] [Full Text] [Related]

  • 8. Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Sidiropoulos PI, Boumpas DT.
    Ann Rheum Dis; 2006 Jun 22; 65(6):701-3. PubMed ID: 16699049
    [Abstract] [Full Text] [Related]

  • 9. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.
    Reumatismo; 2009 Jun 22; 61 Suppl 1():1-23. PubMed ID: 19999184
    [Abstract] [Full Text] [Related]

  • 10. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P.
    Rev Med Interne; 2008 Dec 22; 29(12):971-4. PubMed ID: 18571291
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract] [Full Text] [Related]

  • 12. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis.
    Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, Sugihara T, Nonomura Y, Hirose W, Nagasaka K, Sakurai T, Miyasaka N.
    Mod Rheumatol; 2007 Oct 10; 17(6):531-3. PubMed ID: 18084712
    [No Abstract] [Full Text] [Related]

  • 13. [New treatments for rheumatoid arthritis].
    Girault V, Flipo RM.
    Soins; 2004 Sep 10; (688):37-8. PubMed ID: 15515847
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [TNF targetting therapy for rheumatoid arthritis].
    Takeuchi T.
    Nihon Naika Gakkai Zasshi; 2006 Sep 10; 95(9):1787-94. PubMed ID: 17037316
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
    Titos Arcos JC, Hallal H, Robles M, Andrade RJ.
    Rev Esp Enferm Dig; 2012 May 10; 104(5):282-4. PubMed ID: 22662786
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.